All In Biotech

Drug Trial Radar · NCT07773129

A Study to Learn How ASP3082 is Processed in Healthy Men

A Phase 1, Open-label Study to Evaluate the Metabolism and Excretion of [14C]ASP3082 in Healthy Adult Male Participants

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Aug 28, 2026

Primary completion

Oct 20, 2026

Study completion Oct 20, 2026

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
First posted
Aug 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Setidegrasib (ASP3082) is being developed for certain cancers. In this study, the researchers want to understand how it is processed by the body in healthy male volunteers. To do this, \[14C\] which is a certain chemical (called a tracer, or radionuclide) has been added to setidegrasib. \[14C\] gives off radiation, but the dose is very low (about the same as the dose from an x-ray) and will leave the body within a few days. \[14C\] will be picked up by a scanner and will be used to follow setidegrasib through the body. \[14C\]setidegrasib will be given as 1 single injection slowly through a vein (infusion). The men will stay overnight in the clinic for at least 2 weeks. They will give regular blood, urine and stool samples during their stay and will be closely monitored. The men will return to the clinic about 1 week later for a final safety check.

Conditions

  • Healthy Volunteer

Interventions

  • 14C-labeled ASP3082Drug

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (PK) of 14C-labeled ASP3082 (radioactivity in whole blood): area under the concentration-time curve from the time of dosing extrapolated to time infinity (AUCinf)Time frame: Up to 21 days
  2. PK of 14C-labeled ASP3082 (radioactivity in whole blood): area under the concentration-time curve from the time of dosing to the last measurable concentration (AUClast)Time frame: Up to 21 days
  3. PK of 14C-labeled ASP3082 (radioactivity in whole blood): maximum concentration (Cmax)Time frame: Up to 21 days
  4. PK of 14C-labeled ASP3082 (radioactivity in plasma): AUCinfTime frame: Up to 21 days
  5. PK of 14C-labeled ASP3082 (radioactivity in plasma): AUClastTime frame: Up to 21 days
  6. PK of 14C-labeled ASP3082 (radioactivity in plasma): CmaxTime frame: Up to 21 days
  7. PK of 14C-labeled ASP3082 (radioactivity ratio of whole blood/plasma concentrations): radioactivity ratio of area under the concentration time curve in blood as compared to plasma (AUCblood/AUCplasma)Time frame: Up to 21 days
  8. Excretion of 14C-labeled ASP3082 (radioactivity in urine): amount of administered dose excreted (Ae)Time frame: Up to 21 days
  9. Excretion of 14C-labeled ASP3082 (radioactivity in urine): percentage of administered dose excreted (Ae percentage)Time frame: Up to 21 days
  10. Excretion of 14C-labeled ASP3082 (radioactivity in urine): cumulative (over more than 1 sampling interval) amount of administered dose excreted (CumAe)Time frame: Up to 21 days
  11. Excretion of 14C-labeled ASP3082 (radioactivity in urine): renal clearance (CLr)Time frame: Up to 21 days
  12. Excretion of 14C-labeled ASP3082 (radioactivity in feces): AeTime frame: Up to 21 days
  13. Excretion of 14C-labeled ASP3082 (radioactivity in feces): Ae percentageTime frame: Up to 21 days
  14. Excretion of 14C-labeled ASP3082 (radioactivity in feces): CumAeTime frame: Up to 21 days
  15. Excretion of 14C-labeled ASP3082 (combined radioactivity in urine and feces): AeTime frame: Up to 21 days
  16. Excretion of 14C-labeled ASP3082 (combined radioactivity in urine and feces): Ae percentageTime frame: Up to 21 days
  17. Excretion of 14C-labeled ASP3082 (combined radioactivity in urine and feces): CumAeTime frame: Up to 21 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fortrea Clinical Research Unit Inc.

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.